Investors Show Strong Interest in Hexagon Nutrition IPO, Bids Reach 54 Times
Hexagon Nutrition Limited, a leading research-driven nutrition company, concluded its Initial Public Offering (IPO) with resounding success, achieving an overall subscription of 53.68 times...
AstraZeneca Advances Oral GLP-1 Elecoglipron to Phase III Programme
AstraZeneca announced positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). The data,...
Sun Pharma Gets SBI Support for $12 Billion Organon Acquisition
State Bank of India (SBI) is set to join a global consortium financing Sun Pharmaceutical Industries Ltd.'s landmark USD 12 billion acquisition of Organon & Co.,...
GSK expands deal worth $ 10.6B for lung cancer treatment
GSK plc and Nuvalent, Inc. announced that they have entered into a definitive agreement under which GSK will acquire Nuvalent, a clinical-stage biopharmaceutical company focused on...
Roche Enters BTK Degrader Space with $2.3B Nurix Therapeutics Alliance
Roche and Nurix Therapeutics, Inc. announced a definitive global licensing and collaboration agreement to co-develop and co-commercialize bexobrutideg (NX-5948), an investigational, orally bioavailable Bruton’s Tyrosine Kinase (BTK) degrader. The transaction, valued...
Solaris Pharma Launches Generic Briviact®️ to Improve Access to Epilepsy Treatment
Solaris Pharma has launched brivaracetam tablets — the generic equivalent of UCB's Briviact® — marking a notable pivot for a company long anchored in...